Results 51 to 60 of about 5,275 (178)

Management of gout: Primary care approach

South African Family Practice, 2009
Great strides have been made in understanding gout as a disease over the centuries. Despite these advances, reports suggest that the management of gout is relatively sub-optimal at the primary care level.
Olufemi Omole, Gboyega A. Ogunbanjo
doaj   +1 more source

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source

Critical appraisal of the role of pegloticase in the management of gout

Open Access Rheumatology: Research and Reviews, 2012
Hang-Korng Ea,1,2 Pascal Richette1,21Hôpital Lariboisière, Rheumatology Department, Paris, France; 2University of Paris Diderot, Sorbonne Paris Cité, Paris, FranceAbstract: Gout is a debilitating disease secondary to ...
Ea HK, Richette P
doaj  

Prophylaxis for acute gout flares after initiation of urate-lowering therapy [PDF]

Rheumatology, 2014
This review summarizes evidence relating to prophylaxis for gout flares after the initiation of urate-lowering therapy (ULT). We searched MEDLINE via PubMed for articles published in English from 1963 to 2013 using MEsH terms covering all aspects of prophylaxis for flares.
Augustin, Latourte, Thomas, Bardin, Pascal, Richette   +2 more
openaire   +2 more sources

Exploring a Subpopulation of MASLD Associated With New Onset of CKD Using Supervised Clustering Techniques

Hepatology Research, EarlyView.
The supervised clustering of metabolic dysfunction‐associated steatotic liver disease (MASLD) using a SHapley Additive exPlanations (SHAP)‐converted matrix reveals distinct subpopulations that improved risk stratification for new onset of chronic kidney disease (CKD).
Itaru Hosaka, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keitaro Nishizawa, Rie Matsumori, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Koki Abe, Toru Suzuki, Hidemichi Kouzu, Naoya Yama, Nagisa Hanawa, Masato Furuhashi   +14 more
wiley   +1 more source

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, Volume 78, Issue 3, Page 344-351, March 2026.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, Volume 78, Issue 3, Page 337-343, March 2026.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Moving urate-lowering therapy in gout beyond guideline recommendations

Seminars in Arthritis and Rheumatism
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice ...
Lisa K Stamp, Nicola Dalbeth
openaire   +2 more sources

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source